Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2

Raymond T. Suhandynata¹, Melissa A. Hoffman¹, Deli Huang², Jenny T. Tran², Michael J. Kelner¹, Sharon L. Reed¹, Ronald W. McLawhon¹, James E. Voss², David Nemazee², Robert L. Fitzgerald¹*

1 Department of Pathology UC San Diego Health, San Diego CA
2 Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, CA

*Address correspondence to this author at: UCSD, 10300 Campus Point Dr, San Diego, CA 92121-7721. Fax 858 657-5807; email rfitzgerald@ucsd.edu.

Running title: Serology and Neutralization
Abstract

**Background:** It is unknown whether a positive serology result correlates with protective immunity against SARS-CoV-2. There are also concerns regarding the low positive predictive value of SARS-CoV-2 serology tests, especially when testing populations with low disease prevalence.

**Methods:** A neutralization assay was validated in a set of PCR confirmed positive specimens and in a negative cohort. In addition, 9,530 specimens were screened using the Diazyme SARS-CoV-2 IgG serology assay and all positive results (N=164 individuals) were reanalyzed using the neutralization assay, the Roche total immunoglobulin assay, and the Abbott IgG assay. The relationship between the magnitude of a positive SARS-CoV-2 serology result and neutralizing activity was determined. Neutralizing antibody titers (ID50) were also longitudinally monitored in SARS-CoV-2 PCR confirmed patients.

**Results:** The SARS-CoV-2 neutralization assay had a positive percent agreement (PPA) of 96.6% with a SARS-CoV-2 PCR test and a negative percent agreement (NPA) of 98.0% across 100 negative control individuals. ID50 neutralization titers positively correlated with all three clinical serology platforms. Longitudinal monitoring of hospitalized PCR confirmed COVID-19 patients demonstrated they made high neutralization titers against SARS-CoV-2. PPA between the Diazyme IgG assay alone and the neutralization assay was 50.6%, while combining the Diazyme IgG assay with either the Roche or Abbott platforms increased the PPA to 79.2% and 78.4%, respectively.

**Conclusions:** These three clinical serology assays positively correlate with SARS-CoV-2 neutralization activity observed in COVID-19 patients. All SARS-CoV-2 PCR positive patients develop neutralizing antibodies.

Key words: Neutralizing Antibodies, COVID-19, Serology, Immunity, SARS-CoV-2
Introduction

The 2019 coronavirus pandemic is caused by the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first discovered in Wuhan, China (1,2). As governments across the world struggle to contain the spread of the virus, the worldwide economy has been impacted by the resulting shutdown and social distancing protocols that have been implemented (3–7). As nations begin to “re-open their economies” in stages, a major question that surrounds COVID-19 antibody testing is whether SARS-CoV-2 serology tests can be used to identify individuals with protective immunity against the virus (8). Neutralizing antibodies play a key role in the quest for protective immunity against SARS-CoV-2 (9), and ID50 neutralization titers have been the reference method to assess protective immunity against smallpox, polio, and influenza viruses following vaccine administration (10–12). A number of reports have characterized the clinical performance of commercially available SARS-CoV-2 serology assays (13–20). However, whether commercial SARS-CoV-2 serology platforms correlate with the presence of neutralizing antibodies and protective immunity against COVID-19 still needs further exploration (21–27).

A recent comparison of six SARS-CoV-2 immunoassays and a microneutralization assay against SARS-CoV-2 (28) demonstrated that 41 of 62 COVID-19 patients showed neutralizing antibodies. Here we evaluated the clinical sensitivity and specificity of a pseudovirus based neutralization assay and investigated the correlation between the neutralization assay (29,30) and SARS-CoV-2 serology platforms in a large cohort of clinical specimens. We determined the orthogonality of the Diazyme, Roche, and Abbott assays to initiate a dual immunoassay approach for confirming positive SARS-CoV-2 serology results, as suggested by the Centers for Disease Control and Prevention (31). This screen and confirm approach was applied retrospectively to 9,530 SARS-CoV-2 tests, demonstrating that combining two orthogonal serology assays substantially improved the predictive value for identifying neutralizing antibodies.
Materials and Methods

Study Design and Patient Cohort

The patient cohorts used in this study are illustrated in Figure 1. Briefly, the main cohort (Figure 1A) consisted of 9,530 consecutive specimens (K-EDTA, lithium-heparin plasma separator tubes, and/or serum separator tubes) that were screened at UC San Diego Health using the Diazyme IgG assay from 4/14/20 until 6/12/20. The specimens that were positive using the Diazyme IgG assay (N=164 specimens, N=164 individuals) were separated into subgroups depending on symptoms, if they were admitted, or if they were from a skilled nursing facility. All of the specimens that screened positive with the Diazyme assay were retrospectively tested using the neutralization, Roche, and Abbott assays. A separate cohort (Figure 1B) was used to evaluate the relationship between hospitalized SARS-CoV-2 PCR confirmed positive patients (31 patients, 87 specimens) and the neutralization assay. The last cohort (Figure 1C) was used to evaluate the relationship between SARS-CoV-2 negative specimens (100 specimens from 100 individuals) and the neutralization assay. The negative cohort consisted of 7 patients positive for other coronaviruses (229E, HKU1, NL63, or OC42), 4 Rhinovirus positive patients, 10 apparently healthy individuals, and 79 COVID-19 naïve specimens (individual patients collected in 2018, stored -20°C).

The group (N=251 specimens, N=195 individuals) used to evaluate a cutoff for neutralization activity on each of the commercial serology platforms, shown in Figure 5, included the 164 specimens from 164 individuals that were seropositive for IgG on the Diazyme platform and the 87 specimens from the 31 SARS-CoV-2 PCR confirmed patients (that were also positive on the Diazyme IgG assay). The median number of days post PCR positivity for these 87 specimens from 31 patients was 9 days, with an interquartile range of 5 – 15 days. The median number of days post-symptom onset for these specimens
was 13 days, with an interquartile range of 9 – 18 days. Specimens were split into two groups (Negative and Positive) based on the absence or presence of SARS-CoV-2 neutralization activity.

All patient specimens were collected under UCSD IRB protocol 181656.

**Classification of Symptoms**

Individuals were classified into three groups based on symptom severity. Asymptomatic individuals had no COVID-19 related symptoms (shortness of breath, fever, cough, loss of taste, diarrhea etc.) Mildly symptomatic individuals had mild COVID-19 related symptoms (as above), and did not require hospital admission. Admitted patients had COVID-19 related symptoms and were admitted to the hospital due to the severity of their symptoms upon presentation.

**Confirmation of SARS-CoV-2 Positive Patients**

All 31 SARS-CoV-2 patients were positively confirmed for COVID-19 by an emergency use authorized nucleic acid test that had also been validated in our laboratory (Abbott ID NOW, GenMark ePlex, Abbott RealTime, Roche cobas 6800) (13,20). The Abbott RealTime and cobas 6800 are RT-PCR based tests, while the Abbott ID Now and GenMark ePlex are nucleic acid amplification based tests. For simplicity these patients will be referred to as SARS-CoV-2 PCR confirmed patients.

**Serology**

Serology was performed on the Diazyme DZ-Lite 3000 plus clinical analyzer as previously described for IgG (13). Serology was performed on the Roche Cobas 8000 e801 analyzer (Roche Elecsys Anti-SARS-CoV-2 total Ig) and the Abbott ARCHITECT i1000SR analyzer (Abbott SARS-CoV-2 IgG) according to the manufacturer’s instructions. Plasma (Li-Heparin or K-EDTA) and serum specimens were analyzed in a manner consistent with the package inserts. The Diazyme platform targets antibodies produced against SARS-CoV-2 nucleocapsid (N) and spike (S) proteins, while the Roche and Abbott platforms target only
the N protein. The Diazyme platform reports results as absorbance units per mL (AU/mL); values ≥ 1.00 AU/mL are considered reactive. The Roche platform reports results in the form of a cutoff index (COI; signal of sample/cutoff); values ≥ 1.00 COI are considered reactive. The Abbott platform reports results in the form of an Index value (S/C); Index values ≥ 1.4 S/C are considered reactive. For consistency, we refer to reactive and non-reactive to mean the same as positive and negative throughout this report.

**SARS-CoV-2 and SARS-CoV-1 Pseudovirus Neutralization Assays**

The neutralization assays were performed as previously described using a pseudovirus (PSV) (30). The PSV assay was established for both SARS-CoV-1 and SARS CoV-2 using murine leukemia virus-based PSV. The assay used single cycle infectious viral particles containing firefly luciferase. The amount of luminescence in HeLa cells that stably expressed the cell surface receptor angiotensin converting enzyme 2 were measured after viral infection. Titers of 50% inhibitory dilution (ID50) were determined. An ID50 titer of greater than or equal to 50 was considered a positive neutralization result. The PSV assay was compared with a live replication-competent virus and neutralizing antibodies identified with the assay provided protection against high dose SARS-CoV-2 infection in a hamster animal model (29). All neutralization studies were conducted in a blinded manner.

**GenMark ePlex Respiratory Pathogen Nucleic Acid Test**

The respiratory pathogen nucleic acid test was performed as previously described to confirm patients with other respiratory pathogens (13).

**Calculation of positive percent agreement and negative percent agreement**

Positive percent agreement (PPA) between the Diazyme IgG and Roche assay was calculated by taking the 164 Diazyme IgG screened positives and subsequently testing them on the Roche platform.
Specimens that were positive on the Roche were treated as in agreement and specimens that were negative on the Roche were treated as not in agreement. The PPA was defined as:

\[
PPA = \frac{\text{Specimens in agreement}}{\text{Specimens in agreement} + \text{Specimens not in agreement}} \times 100
\]

This was done in the same manner for calculating PPA between the Diazyme IgG and Abbott assays.

PPA between the neutralization assays and the Diazyme IgG assay was calculated by taking the 164 Diazyme IgG screened positives and testing them for the presence of neutralizing antibodies. Specimens with ID50 neutralization titers >50 were treated as in agreement and specimens with ID50 neutralization titers <50 were treated as not in agreement, and the PPA is defined as above.

Negative percent agreement (NPA) between the neutralization assays and the Diazyme IgG assay was calculated by testing specimens from 100 SARS-CoV-2 PCR negative individuals (Figure 1C) for the presence of neutralizing antibodies. Specimens with ID50 neutralization titers <50 were treated as in agreement and specimens with ID50 neutralization titers >50 were treated as not in agreement. The NPA was then defined as:

\[
NPA = \frac{\text{Specimens not in agreement}}{\text{Specimens not in agreement} + \text{Specimens in agreement}} \times 100
\]

**Statistical Analyses**

Data was analyzed using R in Rstudio and linear regression analysis for all figures were performed in excel or Rstudio. Box and whisker plots were generated in Rstudio. Mann-Whitney and Fishers exact test were performed in R for the box and whisker plots and demographics table, respectively.

**Results**

**Cohort Demographics**
Demographics of the Diazyme IgG seropositive individuals, which were divided based on symptom severity, are shown for age, gender, body mass index, ethnicity, underlying medical conditions, PCR positivity for COVID-19, and positivity for neutralization activity against SARS-CoV-2 in Table 1. Median (interquartile [IQR]) age was significantly different among all three symptom severity groups using the Fishers exact test (P-value <0.0001) with asymptomatic patients being younger. However, no significant difference was observed for body mass index or gender. Significant differences in ethnicity were observed across all three groups (P-value 0.005), with 40% of the admitted group being Hispanic and 63% of the mildly symptomatic group being white. A significant difference was observed for underlying medical conditions (P-value 0.018), 60% of admitted patients had underlying conditions vs 32% in the asymptomatic group. A significant difference (P-value <0.0001) was observed in the percentage of individuals that were positive for COVID-19 by PCR, with 88% of admitted patients having a positive PCR test for SARS-CoV-2 vs 2% testing in the asymptomatic group. A significant difference (P-value <0.0001) was observed across all three groups for the presence of neutralization activity against SARS-CoV-2, with 98% of admitted patients having neutralization activity vs 19% in the asymptomatic group.

Demographics for the 44 Diazyme IgG seropositive patients and staff from skilled nursing facilities could not be retrieved because they were de-identified prior to analysis.

Clinical Evaluation of a SARS-CoV-2 Neutralization Assay

The SARS-CoV-2 neutralization assay detected neutralization activity in 96.6% of specimens from SARS-CoV-2 PCR confirmed patients, and in 2.0% of the SARS-CoV-2 negative specimens (Figure 2). 83.9% of the specimens from SARS-CoV-2 PCR confirmed patients and 14.0% of the SARS-CoV-2 negative specimens had SARS-CoV-1 neutralization activity (Figure 2). SARS-CoV-1 or SARS-CoV-2 neutralization was not detected in 7 patients infected with non-COVID-19 coronaviruses and 4 patients infected with rhinovirus (Supplementary Table 1).
Correlation of ID50 Neutralization Titers to Commercial SARS-CoV-2 Serology Assays

Linear regression analysis was performed to evaluate the relationship between ID50 neutralization titers and three commercially available SARS-CoV-2 serology platforms for PCR confirmed patients (Supplementary Figure 1). All three platforms showed positive correlation to SARS-CoV-2 ID50 titers.

Longitudinal Monitoring of ID50 Neutralization Titers in COVID-19 patients

SARS-CoV-2 ID50 neutralization titers were longitudinally monitored in 13 PCR confirmed SARS-CoV-2 patients. Serial sampling revealed that SARS-CoV-2 ID50 neutralization titers increased with disease progression in 11 of the 13 patients, while the remaining two patients maintained ID50 neutralization titers of ≥ 1000 (Figure 3). Once elevated, neutralization titers appeared to reach a plateau that stayed elevated up to 25 days (longest time tested). Notably, all patients developed high titers by two weeks after becoming PCR positive.

Retrospective Analysis of Diazyme Screened Seropositive Patients

The 164 Diazyme screened IgG seropositive patient specimens were also analyzed on the Roche Total Ig and Abbott IgG SARS-CoV-2 serology platforms. The overall positive percent agreement (PPA) between the Diazyme IgG assay and the Roche total Ig or Abbott IgG assays were 58.5% and 59.1%, respectively (Supplementary Figure 2). The PPA between Diazyme and Roche was 20.6% for asymptomatic individuals, 71.7% for patients with mild symptoms, 90.9% for admitted patients, and 90.9% for patients/staff from skilled nursing facilities (Figure 4A). The PPAs between Diazyme and Abbott were similar to what was observed with the Roche assay (Figure 4A). The percentage of individuals with detectable levels of SARS-CoV-2 neutralization activity in the asymptomatic, mild, admitted, and skilled nursing facility groups (Figure 4B) closely mirror the observed PPAs between the Diazyme IgG and Roche/Abbott platforms for each respective group (Figure 4A). In contrast, the percentage of individuals with detectable levels of SARS-CoV-1 neutralization activity decreased with increasing PPA between
serology platforms (Figure 4B). Overall, 50.6% of Diazyme IgG seropositive individuals (N=164) had detectable neutralization activity, from which a total of 96 and 93 of these individuals were also seropositive on the Roche and Abbott platforms, respectively (Figure 4C). The percentage of specimens that were positive on two serology platforms that had neutralization activity was 79.2% and 78.4% when using the Diazyme + Roche and Diazyme + Abbott, respectively (Figure 4C). Confidence intervals for SARS-CoV-2 ID50 titers across the four different populations that were tested demonstrated significant overlap (Supplementary Table 2). All specimens from PCR confirmed positive patients with a positive serology result by either the Diazyme IgG (N=71), Roche total Ig (N=76), and Abbott IgG (N=75) assays had neutralization activity (>ID50).

Multi-platform Cutoff Evaluation for SARS-CoV-2 Neutralization Activity

Boxplots of the observed responses (AU/mL, COI, S/C) on the Diazyme, Roche, and Abbott platforms, from Diazyme IgG seropositives, which were split based on negative or positive SARS-CoV-2 neutralization activity, are shown in Figure 5. The medians (IQR) for the Diazyme IgG assay were 1.9 (1.2 – 4.3) AU/mL and 14.1 (3.3 – 47.4) AU/mL for the negative and positive groups, respectively. The medians (IQR) for the Roche total Ig assay were 0.1 (0.09 – 3.4) COI and 25.5 (7.5 – 63.6) COI for the negative and positive groups, respectively. The medians (IQR) for the Abbott IgG assay was 0.04 (0.02 – 1.1) S/C and 6.8 (4.2 – 8.2) S/C for the negative and positive groups, respectively. For the group that was positive, the median response value was explored as a predictive cutoff for neutralization activity (Diazyme: 14.1 AU/mL, Abbott: 6.8 S/C, and Roche: 25.5 COI). The percentage of seropositive specimens above these cutoff values that had detectable levels of SARS-CoV-2 neutralization activity (> ID50) were 98.8% for Diazyme, 95.1% for Abbott, and 83.5% for Roche.

Discussion
The SARS-CoV-2 neutralization assay had a PPA of 96.6% with a SARS-CoV-2 PCR test (N=87 specimens, N=31 patients) and a negative percent agreement (NPA) of 98.0% across 100 negative control subjects. Interestingly, 83.9% of specimens from SARS-CoV-2 PCR confirmed patients had neutralizing activity for SARS-CoV-1, which was responsible for the original 2002-2004 SARS epidemic (32–35). This supports the finding that SARS-CoV-2 infected individuals produce neutralizing antibodies that cross-react with SARS-CoV-1 (36). Likewise, neutralization activity against SARS-CoV-1 was observed in 14.0% of COVID-19 negative individuals and could be a result of past exposure to SARS-CoV-1, lower specificity of the SARS-CoV-1 neutralization assay, or greater cross-reactivity to other common coronaviruses. The high agreement between a positive SARS-CoV-2 PCR result and the SARS-CoV-2 neutralization assay suggests that neutralizing antibodies are made quickly in response to viral infection. Overall, the SARS-CoV-2 neutralization assay had PPA and NPA similar to published results for clinically validated SARS-CoV-2 serology assays (13) and provides a direct approach to assess protective immunity against SARS-CoV-2.

Regression analysis of SARS-CoV-2 neutralization titers in SARS-CoV-2 PCR confirmed positive patients correlated with the corresponding values on the Diazyme, Roche, and Abbott platforms. The Diazyme IgG assay had the strongest correlation with SARS-CoV-2 neutralization titers, and could be a result of the linear characteristics of this platform (13). Furthermore, all platforms were highly sensitive for the detection of ID50 neutralization titers greater than 1000 (Supplementary Figure 1). At ID50 titers of greater than 1000, 98.9% of the specimens were seropositive on the Diazyme IgG assay, and 100% of the specimens were seropositive for both the Roche and Abbott platforms. Longitudinal monitoring of SARS-CoV-2 ID50 neutralization titers in PCR confirmed SARS-CoV-2 PCR positive hospitalized patients revealed that all patients developed robust neutralization titers during the course of infection (Figure 3).

Using the Roche or Abbott SARS-CoV-2 serology platforms to confirm specimens initially screened positive on the Diazyme IgG assay demonstrated that nearly 40% of the 164 IgG seropositive individuals would have been classified as false positives by the confirmatory assay. As predicted previously (13), the
percentage of individuals that were retrospectively identified as falsely positive depended greatly on the population of individuals being tested. The retrospective false positive rate was as high as 79.4% in asymptomatic individuals, approximately 30% in individuals with mild symptoms, and potentially 0% in admitted patients. One limitation with using a secondary platform to confirm SARS-CoV-2 seropositive specimens, is that there is no reference assay for COVID-19 serology at this time. Based on prevalence and specificity of this assay it is likely that the discordant specimens observed are false positives, but prudent practice would be to call these specimens indeterminate and ask for repeat testing. Altogether, this emphasizes the effect of disease prevalence on the positive predictive values, and highlights the danger of screening low prevalence populations even when using a highly specific SARS-CoV-2 serology assay.

100% of specimens that tested positive on all three commercially available serology platforms had detectable ID50 titers (> 50) against SARS-CoV-2. In contrast, only 50.6% of the 164 seropositive individuals identified on the Diazyme platform had neutralization titers (Figure 4C), a percentage similar to the PPA between Diazyme and the Roche and Abbott platforms (Figure 4A). However, using the Roche or Abbott platforms to confirm IgG seropositive individuals, would have resulted in nearly 80% of reported seropositive individuals also having neutralization activity against SARS-CoV-2 (Figure 4C). Confidence intervals for SARS-CoV-2 ID50 titers across the four different populations that were tested demonstrated significant overlap (Supplementary Table 2), suggesting that individuals make comparable levels of neutralizing antibodies regardless of symptoms. One limitation of our cohort is that the length of symptom duration for the majority of these 164 individuals was not available, which could affect the neutralizing antibody response that an individual generates. The finding that 80% of two-platform confirmed positive serology results have neutralizing activity is an important result, addressing a major concern when using COVID-19 serology to screen low disease prevalence populations. However, roughly 20% of the two-platform confirmed seropositive individuals did not have SARS-CoV-2
neutralization activity suggesting that a clinically validated SARS-CoV-2 neutralization assay is required for understanding if patients have protective immunity against COVID-19.

In principle, not all COVID-19 patients should have neutralizing antibodies, as these take time to develop after infection, and neutralizing antibodies represent a small subset of antibodies produced (30). It is therefore encouraging that 84 of 87 specimens (96.6%) from SARS-CoV-2 PCR confirmed positive individuals also had neutralizing antibodies, and may encourage more aggressive steroid treatment in patients with symptoms of cytokine storm as production of neutralizing antibodies occurs shortly after infection. We note that the three specimens that did not have neutralizing antibodies were from different patients and these specimens were collected early in the disease process. One was collected two days before the patient became PCR positive and the other two were collected one day after the patient was confirmed positive using PCR. All three patients had neutralizing antibodies on the next specimen that was collected (day 3, 3, and 9). It is therefore important to consider symptom duration when testing for neutralizing antibodies as testing too early in the course of disease could lead to false negative results.

We explored using the median positive serology result as the cutoff value for determining the presence of neutralizing antibodies (Figure 5). Specimens with serology results above the median were highly associated with neutralizing antibodies. 98.9, 95.1 and 83.5% of specimens above the median serology value contained neutralizing antibodies with ID50 titers greater than 50 when using the Diazyme, Abbott and Roche assays respectively.

We observed significant differences (P-value <0.005) in the demographics of 151 Diazyme seropositive individuals that were asymptomatic, mildly symptomatic, and hospital admitted. In particular, although the percentage of Hispanic individuals comprised 25.8% of this population, they accounted for 40% of the hospital admitted cases; of which 98% were PCR positive for COVID-19. This is similar to another
recent report which observed that 60% of all pregnant women hospitalized for COVID-19 were of Hispanic ethnicity (37).

The retrospective analysis of only the 164 seropositive SARS-CoV-2 individuals and not the population of 9,530 individuals is a limitation of the study, preventing a fair comparison of the Diazyme platform with the Roche and Abbott SARS-CoV-2 serology platforms. This is because these individuals were effectively pre-screened for SARS-CoV-2 seropositivity before analysis on either the Roche or Abbott platforms. Moreover, out of the 9,530 tests performed, the estimated overall false positive rate of the Diazyme IgG assay was between 0.7 - 0.9%, and is equal to or lower than its published value of 0.9% (13). This suggests that our findings would have been similar if either the Roche total Ig or Abbott IgG assays were used as the screening platform and not the confirmatory platform, as both assays have been reported to have specificity that exceeds 99% (14–16); emphasizing the dangers of using any one single serology platform to screen low prevalence populations for SARS-CoV-2 serology. Another limitation is that we did not use live virus to perform the neutralization assays, however, Rogers et al. showed a high correlation between the PSV and live virus, indicating that the use of a more hazardous live virus assay may be unnecessary (30). A final limitation is that the 7 patients with other coronaviruses were not serologically tested for the presence of antibodies against these viruses and although they were PCR positive, it cannot be certain that a humoral response had occurred in these patients.

We report a comprehensive retrospective study of 164 SARS-CoV-2 seropositive specimens from 9,530 SARS-CoV-2 serology tests and demonstrate that serology results correlate with neutralization. Our study demonstrates the risk of using a single serology platform to identify SARS-CoV-2 seropositive individuals in low prevalence populations and highlights the benefits of a two-platform approach. Finally, the inclusion of serology and neutralization activity found in mild and asymptomatic cases of COVID-19 are also unique, as cohorts used for other reports are generally of hospitalized patients.
Acknowledgments

We thank all of the staff in the UC San Diego Health clinical laboratories for their help identifying specimens for sensitivity and specificity testing. We also thank Amy Rockefeller and Ernestine Ferrer for valuable technical expertise. We would like to thank Waters Corporation (RTS) and Roche Diagnostics (MAH) for supporting the clinical chemistry fellowship at the University of California-San Diego.

Author Declaration

A version of this article was previously posted as a preprint on medRxiv as https://www.medrxiv.org/content/10.1101/2020.07.10.20150946v1.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

R.T. Suhandynata, statistical analysis; M.A. Hoffman, statistical analysis; D. Huang, statistical analysis; R.W. McLawhon, financial support, administrative support, provision of study material or patients; D. Nemazee, financial support, statistical analysis, provision of study material or patients.

Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest:

Employment or Leadership: None declared.
Consultant or Advisory Role: None declared.
Stock Ownership: None declared.
Honoraria: None declared.
Research Funding: D. Nemazee, NIH.
Expert Testimony: None declared.
Patents: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of manuscript.
References

1. Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020;133:1015–24.

2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727–33.

3. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg Lond Engl 2020;78:185–93.

4. McCall B. Shut down and reboot—preparing to minimise infection in a post-COVID-19 era. Lancet Digit Health 2020;2:e293–4.

5. Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med 2020;27:taaa020.

6. Pak A, Adegboye OA, Adekunle Al, Rahman KM, McBryde ES, Eisen DP. Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness. Front Public Health 2020;8:241.

7. Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)—An emerging global health threat. J Infect Public Health 2020;13:644–6.

8. Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19 Antibody Tests — At What Cost? N Engl J Med 2020;383:e37.

9. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol 2020;41:355–9.

10. Zinkernagel RM. On Natural and Artificial Vaccinations. Annu Rev Immunol 2003;21:515–46.

11. Fenner F. Mouse-Pox (Infectious Ectromelia of Mice): A Review. J Immunol 1949;63:341.

12. Sabin AB. Oral Poliovirus Vaccine: History of Its Development and Use and Current Challenge to Eliminate Poliomyelitis from the World. J Infect Dis Oxford Academic;1985;151:420–36.

13. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. J Appl Lab Med 2020;5:908–20.

14. Favresse J, Eucher C, Elsen M, Marie T-H, Dogné J-M, Douxfils J. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem 2020;66:1104–6.

15. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem 2020;66:1107–9.
16. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. McAdam AJ, editor. J Clin Microbiol 2020;58:e00941-20, /jcm/58/8/JCM.00941-20.atom.

17. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. J Clin Microbiol 2020;

18. Chew KL, Tan SS, Saw S, Pajarillaga A, Zaine S, Khoo C, et al. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clin Microbiol Infect 2020;S1198743X20303347.

19. Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubée V, et al. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol 2020;129:104511.

20. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. Multi-platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19. J Appl Lab Med 2020;jfaa139.

21. “Immunity passports” in the context of COVID-19 [Internet]. [cited 2020 Jun 28]. Available from: https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19

22. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020;26:1478–88.

23. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis 2020;ciaa344.

24. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020;71:778–85.

25. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020;92:1518–24.

26. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020;368:489–93.

27. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581:465–9.

28. Jääskeläinen A, Kuivanen S, Kekäläinen E, Ahava M, Loginov R, Kallio-Kokko H, et al. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol 2020;129:104512.
29. Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 2020;eabc7424.

30. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 2020;eabc7520.

31. CDC. Information for Laboratories about Coronavirus (COVID-19) [Internet]. Cent. Dis. Control Prev. 2020 [cited 2020 Jun 5]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html

32. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, et al. A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med. Massachusetts Medical Society; 2003;348:1977–85.

33. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N Engl J Med. Massachusetts Medical Society; 2003;348:1967–76.

34. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med. Massachusetts Medical Society; 2003;348:1986–94.

35. Demmler GJ, Ligon BL. Severe acute respiratory syndrome (SARS): a review of the history, epidemiology, prevention, and concerns for the future. Semin Pediatr Infect Dis 2003;14:240–4.

36. Lv H, Wu NC, Tsang OT-Y, Yuan M, Perera RAPM, Leung WS, et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep 2020;31:107725.

37. Goldfarb IT, Clapp MA, Soffer MD, Shook LL, Rushfirth K, Edlow AG, et al. Prevalence and Severity of Coronavirus Disease 2019 (COVID-19) Illness in Symptomatic Pregnant and Postpartum Women Stratified by Hispanic Ethnicity. Obstet Gynecol 2020;136:300–2.
Table 1. Demographics of Seropositive Individuals

|                                | Asymptomatic N = 63 | Mild Symptoms N = 46 | Admitted N = 42 | P-value |
|--------------------------------|---------------------|----------------------|----------------|---------|
| **Age (years)**                | 43 (33 - 49)        | 49 (36 - 64)         | 52 (43 - 68)   | < 0.0001|
| **Gender**                     |                     |                      |                | 0.21    |
| Male                           | 33 (52%)            | 25 (54%)             | 29 (69%)       |         |
| Female                         | 30 (48%)            | 21 (46%)             | 13 (31%)       |         |
| **Body Mass Index**            |                     |                      |                | 0.23    |
| Median (IQR)                   | 25 (23 - 29)        | 26 (24 - 28)         | 28 (24 - 30)   |         |
| Not Available                  | 15 (24%)            | 1 (2%)               | 0 (0%)         |         |
| **Ethnicity**                  |                     |                      |                | 0.005   |
| Asian                          | 9 (14%)             | 1 (2%)               | 4 (10%)        |         |
| Black                          | 5 (8%)              | 0 (0%)               | 3 (7%)         |         |
| Filipino                       | 7 (11%)             | 7 (15%)              | 2 (5%)         |         |
| Hispanic                       | 14 (22%)            | 8 (17%)              | 17 (40%)       |         |
| Mixed                          | 3 (5%)              | 0 (0%)               | 1 (2%)         |         |
| White                          | 20 (32%)            | 29 (63%)             | 15 (36%)       |         |
| Not Available                  | 5 (8%)              | 1 (2%)               | 0 (0%)         |         |
| **Underlying Medical Conditions**|                    |                      |                | 0.018   |
| Yes                            | 20 (32%)            | 19 (41%)             | 25 (60%)       |         |
| **COVID-19 PCR**               |                     |                      |                | < 0.0001|
| Negative                       | 54 (86%)            | 17 (37%)             | 5 (12%)        |         |
| Positive                       | 1 (2%)              | 15 (33%)             | 37 (88%)       |         |
| Not Tested                     | 8 (13%)             | 14 (30%)             | 0 (0%)         |         |
| **Neutralization Activity (SARS-CoV-2)** |                |                      |                | < 0.0001|
| Negative                       | 51 (81%)            | 25 (54%)             | 1 (2%)         |         |
| Positive                       | 12 (19%)            | 21 (46%)             | 41 (98%)       |         |

IQR, interquartile range
Figures

**Fig. 1.** Flowcharts of the cohorts used for A) Main cohort, B) SARS-CoV-2 PCR positive cohort, and C) SARS-CoV-2 negative cohort. SNF, skilled nursing facility, RPNA, respiratory pathogen nucleic acid.
**Fig. 2.** COVID-19 patients produce neutralization activity against SARS-CoV-2 and SARS-CoV-1. Percentage of specimens (N=87) from SARS-CoV-2 PCR confirmed patients (N=31, dark grey) and a SARS-CoV-2 negative patient cohort (N=100 specimens from 100 individuals, light grey) that had ID50 titers >50 against SARS-CoV-2 or SARS-CoV-1.

|                  | SARS-CoV-1 Neutralization Assay (% of Samples with ID50 Titors > 50) | SARS-CoV-2 Neutralization Assay (% of Samples with ID50 Titors > 50) |
|------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| SARS-CoV-2 Positive n=87 | 83.9%                                                              | 96.6%                                                              |
| SARS-CoV-2 Negative n=100   | 14.0%                                                              | 2.0%                                                               |

**Fig. 3.** Longitudinal monitoring of SARS-CoV-2 neutralization titers in COVID-19 patients. The ID50 titers of 13 SARS-CoV-2 PCR confirmed patients are plotted on a semi-log scale (Y-axis) with the number of days following a positive PCR result indicated for each sample (X-axis). ID50 values of <50 are considered negative for neutralization activity and represented by the greyed-out area.
**Fig. 4.** Interplatform agreement between serology and neutralization activity. A) The positive percent agreement (PPA) between the Diazyme IgG and Roche assay and the Diazyme IgG and Abbott assays are shown for 4 different populations of individuals. B) The percentage of individuals with neutralization activity against SARS-CoV-2 or SARS-CoV-1 are shown for 4 different populations of individuals. C) The overall PPA between the Diazyme IgG assay alone and in combination with the Roche or Abbott serology platforms with SARS-CoV-2 neutralization activity are indicated for 164 seropositive individuals identified on the Diazyme IgG platform.
**Fig. 5.** Distribution of commercial serology platform results in specimens negative and positive for SARS-CoV-2 neutralization activity that initially screened positive by the Diazyme IgG assay. Median AU/mL, COI, and S/C values (Y-axis) on the Diazyme IgG, Roche total Ig, and Abbott IgG platforms, respectively, are shown in boxplots (whiskers are up to but no greater than 1.5 times the IQR) for specimens without (negative) or with (positive) ID50 neutralization titers against SARS-CoV-2 (X-axis). **** indicates significant difference between positive and negative group at a p value of <0.00001 by Mann-Whitney.